Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka Files Novel ADHD Drug Centanafadine in US
Otsuka Pharmaceutical has submitted a new drug application to the US FDA for centanafadine for the treatment of attention-deficit hyperactivity disorder (ADHD), the company said on November 25.The filing is supported primarily by the results from four US PIII trials…
To read the full story
Related Article
- FDA Approves Otsuka’s ADHD Drug Simtriyo
July 28, 2026
- Otsuka’s Centanafadine Meets PIII Goal in ADHD Patients with Anxiety
June 26, 2026
- Otsuka’s Centanafadine Accepted for FDA Review with Priority Tag
January 28, 2026
- Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
October 30, 2023
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- 1 in 4 Epilepsy Patients Dissatisfied with Current Drugs: Survey
October 7, 2026
- Fujifilm Adds Linker-Payload Capacity to Build One-Stop ADC CDMO Service
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…